- Home
- QS vs JAZZ Comparison
QS vs JAZZ Comparison
Compare QS & JAZZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QS
- JAZZ
- Stock Information
- Founded
- QS 2010
- JAZZ 2003
- Country
- QS United States
- JAZZ Ireland
- Employees
- QS N/A
- JAZZ N/A
- Industry
- QS Auto Parts:O.E.M.
- JAZZ Biotechnology: Pharmaceutical Preparations
- Sector
- QS Consumer Discretionary
- JAZZ Health Care
- Exchange
- QS Nasdaq
- JAZZ Nasdaq
- Market Cap
- QS 8.8B
- JAZZ 8.2B
- IPO Year
- QS N/A
- JAZZ 2007
- Fundamental
- Price
- QS $15.63
- JAZZ $136.93
- Analyst Decision
- QS Sell
- JAZZ Strong Buy
- Analyst Count
- QS 6
- JAZZ 14
- Target Price
- QS $5.88
- JAZZ $179.43
- AVG Volume (30 Days)
- QS 55.7M
- JAZZ 649.4K
- Earning Date
- QS 10-22-2025
- JAZZ 11-05-2025
- Dividend Yield
- QS N/A
- JAZZ N/A
- EPS Growth
- QS N/A
- JAZZ N/A
- EPS
- QS N/A
- JAZZ N/A
- Revenue
- QS N/A
- JAZZ $4,086,695,000.00
- Revenue This Year
- QS N/A
- JAZZ $5.75
- Revenue Next Year
- QS N/A
- JAZZ $6.09
- P/E Ratio
- QS N/A
- JAZZ N/A
- Revenue Growth
- QS N/A
- JAZZ 4.52
- 52 Week Low
- QS $3.40
- JAZZ $95.49
- 52 Week High
- QS $19.07
- JAZZ $148.06
- Technical
- Relative Strength Index (RSI)
- QS 54.92
- JAZZ 55.63
- Support Level
- QS $15.02
- JAZZ $136.38
- Resistance Level
- QS $17.45
- JAZZ $140.00
- Average True Range (ATR)
- QS 1.64
- JAZZ 3.01
- MACD
- QS -0.22
- JAZZ -0.32
- Stochastic Oscillator
- QS 42.48
- JAZZ 59.54
About QS QuantumScape Corporation
QuantumScape Corp is engaged in the development of next-generation solid-state lithium-metal batteries for use in electric vehicles and other applications. The company's solid-state lithium-metal battery technology is designed to offer greater energy density, faster charging, and enhanced safety. Its battery cells have none of the host materials used in conventional anodes.
About JAZZ Jazz Pharmaceuticals plc (Ireland)
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.